

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number  
**WO 2004/112801 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/66**,  
31/505, 31/506, A61P 35/00

(21) International Application Number:  
PCT/GB2004/002624

(22) International Filing Date: 18 June 2004 (18.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0314097.7 18 June 2003 (18.06.2003) GB  
0316181.7 10 July 2003 (10.07.2003) GB

(71) Applicant (for all designated States except US): **ANGIO-  
GENE PHARMACEUTICALS LIMITED** [GB/GB];  
14 Plowden Park, Aston Rowant, Watlington Oxfordshire  
OX9 SX (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **RYAN, Anderson,**  
**Joseph** [GB/GB]; AstraZeneca R & D Alderley, Alderley  
Park, Macclesfield Cheshire SK10 4TG (GB).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,  
S-151 85 Sodertalje (SE).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

(88) Date of publication of the international search report:  
24 March 2005

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS COMPRISING ZD6126 TOGETHER WITH 5-FU, CPT-11 OR 5-FU AND CPT-11 HAVING VAS-  
CULAR DAMAGING ACTIVITY FOR TREATING E.G. COLORECTAL CANCER

(57) Abstract: A method for the production of a vascular damaging effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer involving a solid tumour, such as colorectal cancer, which comprises one of: the administration of ZD6126 in combination with 5-FU; the administration of ZD6126 in combination with CPT-11; and the administration of ZD6126 in combination with 5-FU and CPT-11. Also claimed are pharmaceutical compositions and kits comprising one of: ZD6126 and CPT-11; and ZD6126 and 5-FU and CPT-11. Further claimed is use of one of: ZD6126 and 5-FU; ZD6126 and CPT-11; and ZD6126 and 5-FU and CPT-11, in the manufacture of a medicament for use in the production of a vascular damaging effect in a warm-blooded animal which is optionally being treated with ionising radiation.

WO 2004/112801 A3